Сomparative Analysis of Postoperative Pain Syndrome in Cardioesophageal Cancer
Downloads
Postoperative pain syndrome
(POPS) remains a significant clinical challenge in
patients undergoing surgery for cardioesophageal
cancer (CEC). Despite the implementation of
multimodal analgesia protocols, adequate pain
control is not consistently achieved. This study
aimed to comparatively assess postoperative pain
intensity depending on the type of surgical access
and tumor characteristics in patients with CEC.
Eighty-five patients who underwent open surgical
treatment were evaluated using the Numeric Rating
Scale (NRS). Pain intensity was analyzed in
relation to surgical approach, tumor phenotype,
disease stage, and demographic factors. The
highest pain intensity was observed in patients who
underwent
thoracophrenicolaparotomy.
Multimodal analgesia improved pain control;
however, pain levels exceeded the adequate
analgesia threshold (>4 points) in a substantial
proportion of patients. The findings indicate that
postoperative pain intensity is primarily associated
with the extent of surgical trauma rather than
gender or age factors, highlighting the need for
optimization of regional analgesia techniques in
oncologic surgery.
[1] J. L. Apfelbaum, C. Chen, S. S. Mehta, and T. J. Gan, “Postoperative pain experience:
Results from a national survey suggest postoperative pain continues to be undermanaged,”
Anesthesia & Analgesia, vol. 97, no. 2, pp. 534–540, 2003.
[2] R. Chou, D. B. Gordon, O. A. de Leon-Casasola, et al., “Management of postoperative pain:
A clinical practice guideline from the American Pain Society,” The Journal of Pain, vol. 17,
no. 2, pp. 131–157, 2016.
[3] T. J. Gan, “Poorly controlled postoperative pain: Prevalence, consequences, and
prevention,” Journal of Pain Research, vol. 10, pp. 2287–2298, 2017.
[4] H. Kehlet and J. B. Dahl, “Anaesthesia, surgery, and challenges in postoperative recovery,”
The Lancet, vol. 362, pp. 1921–1928, 2003.
[5] F. Lordick, K. Shitara, and Y. Y. Janjigian, “New agents on the horizon in gastric and
gastroesophageal junction cancer,” Journal of Clinical Oncology, vol. 40, no. 16, pp. 1767
1778, 2022.
[6] E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. van Grieken, and F. Lordick, “Gastric cancer,”
The Lancet, vol. 390, pp. 635–648, 2017.
[7] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global cancer statistics 2020: GLOBOCAN
estimates of incidence and mortality worldwide,” CA: A Cancer Journal for Clinicians, vol.
71, no. 3, pp. 209–249, 2021.
[8] World Health Organization, “Palliative care: Key facts,” Geneva, Switzerland: WHO, 2020.
Copyright (c) 2026 American Journal of Biomedicine and Pharmacy

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

